anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Kinesio taping was applied to the study group to improve posture and improve function in the shoulder area. Measurements were carried out for the study group before and after application (with tape on). The tape was then removed and the measurements were repeated after 1 week.
Patients receive ZEN003694 PO QD on days 1-28 of each cycle, cetuximab IV over 120 minutes on days 1 and 15 of each cycle, and encorafenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA, CT or MRI, and collection of blood samples throughout the trial. Patients may also undergo biopsy at screening and on study.
PURPOSE: To obtain a hair cosmetic which has excellent effect to give good feeling without oily or greasy hair touch and prevent hairs branching and damaging by using a specific acylated compound. CONSTITUTION: This hair cosmetic contains a salt of an acylated product obtained by condensation reaction between a fatty acid comprising >=40% of a 20-32C branching fatty acid and a peptide derived from silk protein. The fatty acid is preferably lanolin fatty acid containing >=20wt.% of anteiso branching fatty acid in the branching fatty acid. The peptide derived from the silk protein is preferably a hydrolyzate with a molecular weight of 300-600. The condensate is prepared, e.g. by acylating the silk protein with an acid chloride of the branching fatty acid at a pH of 8-9.5 and the product is an aqueous solution containing 30-40wt.% of the condensate in the solid state. The aqueous solution can used as a cosmetic, as it is or in the form of a powder after dried, and formulated to the cosmetic in an amount of 0.01-20wt.%.
The invention provides compositions and methods for specific binding to a region of the polymeric immunoglobulin receptor (pIgR) of a cell with the provisos that the ligand does not substantially bind to the most abundant form of the secretory component (SC) of pIgR present in an organ of interest of an animal of interest under physiological conditions, and does not bind to the pIgR stalk. In some embodiments, the ligand decreases cleavage of SC from the stalk by at least one-third. The ligands and methods of the invention can be used with both birds and mammals. In more preferred embodiments, the animal is a mammal. In the most preferred embodiment, the animal is a human. The ligand may be targeted into the cell or may undergo retrograde transcytosis and release at the basolateral side of the cell, and may comprise a biologically active composition.
An object of the present invention is to offer novel purine derivatives which exhibit an inhibitory action to nasal mucus secretion and are useful as pharmaceuticals, etc. and pharmaceutically acceptable salts thereof. The purine derivatives of the present invention are novel compounds which are represented by the following general formula (I). <CHEM> [In the formula, R is alkyl or cycloalkyl, or optionally-substituted phenyl or phenylalkyl; R' is hydrogen or -COOX; and X is alkyl, alkenyl, alkoxyalkyl, phenyl or phenylalkyl] The compounds of the present invention are useful as therapeutic and preventive agents to various types of rhinitis accompanied by acceleration of nasal mucus secretion and by sneezing reflex such as allergic rhinitis. Moreover, the compounds of the present invention are able to be administered orally and exhibit low toxicity, little side effect and high safety. Accordingly, a continuous administration for long term is possible and they have a very high utility as the drugs.
Fifty individuals of both sexes will be recruited, previously evaluated by complete clinical / laboratory examination and medical history. The elderly will be excluded from antiinflammatory, chemotherapeutic, corticoid, allergy and bean aversion or antibiotic therapy. These drugs could interfere with protein bioavailability. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, elderly will be eat the bean enrichment of deuterium for availability protein, collected urine or saliva depend on the best biological samples of pilot study (adult).
Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, POL7080; Period 2, Amikacin; Period 3,POL7080+Amikacin. Each period is separated by a wash-out period of at least 12 days between last dose and start of next treatment.
This arm of the study will be randomly assigned to receive a sham device that mirrors that of the active vagal nerve stimulator devices. The sham device arm will experience two 45-minute sessions daily of placebo vagal nerve stimulation until their Nasogastric (NG) tube is removed.
PURPOSE:To obtain a bulb of eye preserving solution for cornea graft comprising hyaluronic acid, one polymer substance of organism, having high viscoelasticity and extremely high water retention, capable of reducing swelling properties of cornea during storage or its physiologically permissible salt. CONSTITUTION:A bulb of eye preserving solution for cornea graft comprises hyaluronic acid or its physiologically permissible salt (especially preferably one having 50,000-250,000 molecular weight). The amount of hyaluronic acid or its physiologically permissible salt is preferably 0.05-0.5wt/vol.% per preserving solution. The osmotic pressure of the bulb of eye preserving solution for cornea graft is preferably adjusted to 260-350 mOsm. An extracted whole bulb of eye or corneal piece is stored in the preserving solution. The preserving solution has low swelling properties of cornea, has low influence on corneal endothelia cell and is excellent.
PURPOSE: To obtain an aqueous gel for cosmetics good in feeling in use and capable of preventing drying of the skin by including small spheroids of a solid hydrophobic lipoid-like material, which melts when applied to bodies, in a continuous phase in a suspended state. CONSTITUTION: This aqueous gel for cosmetics contains 1.5-10wt.% of spheroids having 50-10000μm (preferably 100-3000μm) average particle size of a solid hydrophobic lipoid-like material which melts when applied to bodies in a continuous phase with a suspended state. The spheroid has 30-45C melting point and is selected from a group consisting of triglycerides of 8-18C straight chain fatty acids, butter or solid fractions of plant fats and silicone waxes. The spheroids can carry 1-40wt.% cosmetic components (e.g. a fragrant agent, an essential oil, a pigment, a filler, a grinding material) based on their weight. The composition can contain 0.02-70wt.% of a gelling agent based on the total weight of the gel.
Patients in this group will continue their usual treatment without any intervention. Patients in this control group will undergo a complete clinical and neural evaluation at the beginning and end of a defined period, similar to the NF intervention period, and a clinical follow-up (after 10-12 months).
Hearing loss affects approximately 18% of the population worldwide. Hearing difficulties in noisy environments without accompanying audiometric threshold shifts likely affect an even larger percentage of the global population. One of the potential causes of hidden hearing loss is cochlear synaptopathy, the loss of synapses between inner hair cells (IHC) and auditory nerve fibers (ANF). These synapses are the most vulnerable structures in the cochlea to noise exposure or aging. The loss of synapses causes auditory deafferentation, i.e., the loss of auditory afferent information, whose downstream effect is the loss of information that is sent to higher-order auditory processing stages. Understanding the physiological and perceptual effects of this early auditory deafferentation might inform interventions to prevent later, more severe hearing loss. In the past decade, a large body of work has been devoted to better understand hidden hearing loss, including the causes of hidden hearing loss, their corresponding impact on the auditory pathway, and the use of auditory physiological measures for clinical diagnosis of auditory deafferentation. This review synthesizes the findings from studies in humans and animals to answer some of the key questions in the field, and it points to gaps in knowledge that warrant more investigation. Specifically, recent studies suggest that some electrophysiological measures have the potential to function as indicators of hidden hearing loss in humans, but more research is needed for these measures to be included as part of a clinical test battery.
Patients in the sham VR group will receive the same Meta Quest 2 device but will only have access to a distraction-based VR therapy program that includes 2D nature videos (e.g., relaxing on a beach, swimming with dolphins). Similar to the SynerGI arm, people in the sham VR group will have daily sessions over the 8-week treatment period and be instructed to watch a video for 5-20 minutes each day.
Carcinogenicity and mutogenicity studies have not been conducted. However, radiation is a potential carcinogen and mutagen.

No animal studies have been performed to determine the effects of Zevalin on fertility in males or females. In clinical studies, the Zevalin therapeutic regimen results in a significant radiation dose to the testes: the radiation dose to the ovaries has not been established [see Dosage and Administration (2.5)]. There is a potential risk that the Zevalin therapeutic regimen could cause toxic effects on the male and female gonads. Effective contraceptive methods should be used during treatment and for up to 12 months following the Zevalin therapeutic regimen.
Background and Aim: Major Depressive Disorder(MDD) is a globally leading cause of disability. Currently, psychotherapies like Eye Movement Desensitization and Reprocessing(EMDR) and Cognitive Behavioral Therapy(CBT) are widely available. Since EMDR originated in the United States, it may not be completely appropriate for non-Western countries like Pakistan, necessitating possible modifications. Moreover, therapists have long practiced face-to-face EMDR, but recently, online EMDR modalities have emerged. Nonetheless, it is surprising that there is a dearth of research not only on adaptations of EMDR in Pakistan but also on testing its clinical efficacy, particularly its online modalities. Considering this, the present study aims to develop a culturally and methodologically adapted EMDR therapy protocol, and clinically evaluate its efficacy in treating MDD in Pakistan by comparatively administering it through in-person and online modalities. Methods: This study will employ a mixed mode Randomized Controlled Trial design with a consecutive sample of (n=90). Patients will be treated by using adapted EMDR therapy protocol. Patients will be randomly allocated to in-person and online modes of EMDR. Various qualitative methods and quantitative techniques will be employed to data. Conclusion: This study is likely to make significant contributions by delivering insights about how to develop culturally and methodologically adapted EMDR. This study will extend our knowledge about the comparative effectiveness of EMDR in Pakistan.
PURPOSE: An agent for preventing or treating respiratory diseases, containing Polygoni cuspidati Radix extract is provided to suppress 5-lipoxygenase, airway contraction, and airway inflammation. CONSTITUTION: A composition for preventing or treating respiratory diseases contains Polygoni cuspidati Radix fraction as an active ingredient. The fraction is prepared by extracting Polygoni cuspidati Radix with low alcohol of C1-4 or 10-95% alcohol solution to prepare a crude extract and purifying the fraction with ethyl acetate, dichloromethane, or butanol. A functional food for preventing or treating respiratory diseases contains the fraction as an active ingredient. The content of the extract is 0.01-99.9 wt%. A daily dose of the composition is 0.001-500 mg/kg.
Myelomeningocele (MMC) is a congenital birth defect of the spine and spinal cord, commonly treated clinically through prenatal or postnatal surgery by repairing the unclosed spinal canal. Having previously developed a PLA/PCL polymer smart patch for this condition, we aim to further expand the potential therapeutic options by providing additional cellular and biochemical support in addition to its mechanical properties. Bone morphogenetic proteins (BMPs) are a large class of secreted factors that serve as modulators of development in multiple organ systems, including the CNS. We hypothesize that our smart patch mitigates the astrogenesis induced, at least partly, by increased BMP activity during MMC. To test this hypothesis, neural stem or precursor cells were isolated from rat fetuses and cultured in the presence of Noggin, an endogenous antagonist of BMP action, with recombinant BMPs. We found that the developed PLA/PCL patch not only serves as a biocompatible material for developing neural stem cells but was also able to act as a carrier for BMP-Notch pathway inhibitor Noggin, effectively minimizing the effect of BMP2 or BMP4 on NPCs cultured with the Noggin-loaded patch.
The present invention provides compositions and methods useful for treating, preventing or slowing the progression of ONJ and ORNJ. The invention provides for the use of PDGF in a pharmaceutically acceptable buffer in the preparation of a medicament useful for treating, preventing or slowing the progression of ONJ and ORNJ. The invention provides for the use of PDGF in a pharmaceutically acceptable buffer wherein the PDGF is disposed in a biocompatible matrix in the preparation of a medicament useful for treating, preventing or slowing the progression of ONJ and ORNJ. In one embodiment, a method for treating, preventing or slowing the progression of ONJ or ORNJ comprises providing a composition comprising a PDGF solution disposed in a biocompatible matrix and applying the composition to a desired site in the jaw. In another embodiment, a method for treating, preventing or slowing the progression of ONJ or ORNJ comprises providing a composition comprising a PDGF in a pharmaceutically acceptable buffer and applying the composition to a desired site in the jaw. The present invention also provides kits useful for treating, preventing or slowing the progression of ONJ and ORNJ.
Participants in the intervention group (swSEP) will receive standard preoperative physiotherapy education in addition to a Fitbit Aspire 3 wearable device, which will track vital signs such as heart rate, physical activity, and sleep patterns. They will follow a personalised exercise program that is remotely supervised by a physiotherapist via telemedicine twice a week. The exercise regimen will consist of 20-minute sessions, at least three times per week, and will include three core components: strength training, aerobic exercise, and flexibility exercises. Strength training will involve 2-3 sets of full-body exercises, including combinations of upper body, lower body, and abdominal movements. Aerobic exercises will be performed at a minimum intensity of 40% of the participant's maximal heart rate (HRmax) for up to 20 minutes. Flexibility training will include six stretches, each held for 20 seconds and repeated twice, targeting the chest, arms, legs, and trunk.
OBJECTIVE: Evaluation of the effect of Neuromidine on the dynamics of pain syndrome in the treatment of patients with discogenic lumbosacral radiculopathy.
MATERIAL AND METHODS: Patients with a confirmed diagnosis of discogenic lumbosacral radiculopathy no more than one year old and moderate intensity of pain syndrome on a visual analog scale were included in the main group (OH, n=62, age - 53.1±15.6 yrs) and the comparison group (HS, n=40, age - 53.7±12.9 yrs). OG patients received Neuromidine (15 mg/1 mL 1 once a day IM for 10 days, then 20 mg 3 times a day for 8 weeks) in addition to the standard drug therapy, HS patients received only standard drug therapy. The duration of the study was 8 weeks. The degree of decrease in the intensity and dynamics of pain syndrome, activity and frequency of pain in the lumbar spine, changes in the level of physical activity, and the severity of emotional disorders were evaluated. The level of inflammatory markers in the blood and the dynamics of monosynaptic spinal H-reflex parameters were evaluated.
RESULTS: Before the study, there were no statistically significant differences there were no results of clinical and laboratory-instrumental examination between groups. After 8 weeks, the reduction of pain by VAS in the main group was statistically significant in contrast to the comparison group (p=0.0001). In the main group there was a statistically significant increase in the mean cognitive impairment score (p=0.0029), as well as an improvement in psycho-emotional state with a significant decrease in GAD-7 (p=0.0002) and PHQ-9 (p=0.0096). After 8 weeks of therapy, IL-6 level in the main group was statistically significantly lower (p=0.0027) than in the comparison group. The results of H-reflex study revealed an increase in its amplitude and some shortening of latency at the end of Neuromidine therapy. The drug had no undesirable side effects and was well tolerated.
CONCLUSION: Administration of Neuromidine 15 mg/1 ml once a day intramuscularly for 10 days followed by 20 mg 3 times a day for 8 weeks has an effective analgesic effect as adjuvant therapy in patients with discogenic lumbosacral radiculopathy. The inclusion of Neuromidine in the complex treatment of patients with pain syndrome in discogenic radiculopathy is superior in efficacy to standard drug therapy.
The control group received multi-course includes exercise and nutrition, 1 time per week, 2 hours each time, a total of 12 times, and each unit is 50 minutes long. The three measurement time points of the tracking effect were: before intervention, after 4-times interventions, and after 12-times interventions. The following data were collected in the two groups: frailty assessment, grip strength, lower limb muscle strength, health literacy scale and nutrition knowledge scale.
BACKGROUND: The ability to walk is an important factor in quality of life after stroke. Co-activation of hip adductors and knee extensors has been shown to correlate with gait impairment. We have shown previously that training with a myoelectric interface for neurorehabilitation (MINT) can reduce abnormal muscle co-activation in the arms of stroke survivors.
METHODS: Here, we extend MINT conditioning to stroke survivors with leg impairment. The aim of this pilot study was to assess the safety and feasibility of using MINT to reduce abnormal co-activation between hip adductors and knee extensors and assess any effects on gait. Nine stroke survivors with moderate to severe gait impairment received 6 h of MINT conditioning over six sessions, either in the laboratory or at home.
RESULTS: MINT participants completed a mean of 159 repetitions per session without any adverse events. Further, participants learned to isolate their muscles effectively, resulting in a mean reduction of co-activation of 70% compared to baseline. Moreover, gait speed increased by a mean of 0.15 m/s, more than the minimum clinically important difference. Knee flexion angle increased substantially, and hip circumduction decreased.
CONCLUSION: MINT conditioning is safe, feasible at home, and enables reduction of co-activation in the leg. Further investigation of MINT's potential to improve leg movement and function after stroke is warranted. Abnormal co-activation of hip adductors and knee extensors may contribute to impaired gait after stroke. Trial registration This study was registered at ClinicalTrials.gov (NCT03401762, Registered 15 January 2018, https://clinicaltrials.gov/study/NCT03401762?tab=history&a=4 ).
The invention discloses a cellulase-based assisted extraction method of cinnamon polyphenols. The method comprises the following steps: adding a cellulase which accounts for 0.15 wt% of the total dry cinnamon powder, carrying out enzymolysis, adding distilled water, and decocting. An orthogonal experiment process is utilized to optimize the cellulase-enzymolysis assisted extraction technique of cinnamon polyphenols, thereby providing scientific references for research and development. A single factor and orthogonal experiment is utilized to research the cellulase assisted extraction technique of cinnamon polyphenols. The optimum extraction technique parameters of cinnamon polyphenols are as follows: the temperature is 100 DEG C, the extraction time is 60 minutes, the material/liquid ratio is 1:25, the pH value is 5.2, the cinnamon polyphenol yield is 3.23%, and the total polyphenol content is 35.2%. The result indicates that the cinnamon polyphenol has higher oxidation-resistant activity (IC50 is 41.02 mu g/mL), and the maximum clearance rate for hydroxy free radicals is 97.1% when the concentration is 200 mu g/mL.
PURPOSE: To obtain a peroxide-hydrogencarbonate two-component oral compsn. hardly causing the decomposition of spices and decomposition by the spices even after stored for a long period of time. CONSTITUTION: This oral compsn. contains 1st and 2nd compsns. at a weight ratio of about 2:1 to 1:20 held at separate positions in a vessel. The 1st compsn. contains about 0.1-10 wt.% peroxide and such an effective amt. of a 1st spice as to impart flavor and taste. The 2nd compsn. contains about 0.5-80 wt.% hydrogencarbonate and such an effective amt. of a 2nd spice as to impart flavor and taste. The 1st spice is selected from among methyl salicylate, cinnamic aldehyde, clove oil and a combination of them and reacts with the hydrogencarbonate. The 2nd spice is menthol and does not react with the hydrogencarbonate.
The present invention relates to a method of enhancing an immune response to a pathogen in a host using intranasal administration of interleukin-12 (IL-12). In one embodiment, the present invention relates to a method of inducing an immune response to a pathogen in a host, which comprises administering intranasally to the host an effective amount of IL-12 and an antigen of the pathogen. In another embodiment, the present invention relates to a method of enhancing an immune response to a pathogen in a host, which comprises administering intranasally to the host an effective amount of IL-12 and an antigen of the pathogen. In a particular embodiment, the present invention relates to a method of inducing an immune response to a mucosal pathogen in a host, which comprises administering intranasally to the host an effective amount of IL-12 and an antigen of the pathogen. Also encompassed by the present invention is a method of inducing a Th1-like immune response to a pathogen in a host, comprising administering intranasally to the host an effective amount of IL-12 and an antigen of the pathogen. The present invention also relates to a method of enhancing a mucosal immune response to a pathogen in a host, which comprises administering intranasally to the host an effective amount of IL-12 and an antigen of the pathogen.